Abstract
At JADPRO Live 2024, Megan B. May, PharmD, BCOP, FAPO, FHOPA, provided an overview of recent advances in therapies for solid tumors, highlighting 42 new FDA-approved indications between October 2023 and October 2024. Dr. May discussed pivotal trial results, mechanisms of action, indications, and management strategies for drugs in lung, breast, melanoma, rare tumors, and more. The presentation also emphasized the importance of biomarker-driven therapies and next-generation sequencing.
